New Horizon Medical Solutions has announced a strategic collaboration with Soring, the U.S. affiliate of Söring, for the sale of their Ultrasonic Wound Debridement device. This partnership aims to enhance wound treatment across multiple medical environments by integrating advanced technology with clinical solutions.
The Söring Ultrasonic-Assisted Wound debridement system consists of an ultrasonic generator and instrument designed for debridement and wound cleansing. The technology targets chronic and acute wounds, including those associated with diabetic foot syndrome, decubitus ulcers, burns, and post-surgical or post-traumatic injuries. The system works to remove fibrin tissues such as necroses, fibrin, scab, and pus while breaking up biofilms that can impede healing.
Jeffrey Alan Niezgoda, MD, Chief Medical Officer of Kent Imaging and board member of NHMS, emphasized the potential clinical impact of integrating this technology with existing diagnostic tools. "The use of SONOCA 185 and the UAW instruments for Ultrasonic Wound Debridement guided by SnapshotGLO and monitored by SnapshotNIR can significantly improve wound management and lead to better patient outcomes," Niezgoda stated. He noted that these devices work synergistically to optimize wound bed preparation prior to the application of Cellular and/or Acellular Matrices and Placental tissues.
Will Hall, CEO of New Horizon Medical Solutions, explained the strategic rationale behind the collaboration. "This collaboration reflects our belief that the future of wound care lies in combining advanced technology with evidence-based clinical solutions," Hall said. "By bringing Söring's ultrasonic system into our portfolio, we're expanding access to innovative tools that address critical gaps in treatment while improving efficiency and outcomes across care settings."
The partnership represents a convergence of specialized medical technologies. New Horizon Medical Solutions focuses on biologically derived human placental allograft products, while Söring specializes in ultrasonic tissue resection and ablation technologies. Founded in 1985 and headquartered in Germany, Söring develops medical technologies used by healthcare professionals worldwide with a focus on making surgical procedures more efficient, safer, and easier to perform.
For business and technology leaders in healthcare, this collaboration signals several important industry trends. First, it demonstrates the growing importance of integrated technology solutions in wound care, where diagnostic, therapeutic, and monitoring systems work together to improve outcomes. Second, it highlights the strategic value of partnerships between companies with complementary expertise, allowing for more comprehensive solutions than either could provide independently.
The implications for healthcare providers include potential improvements in treatment efficiency and patient outcomes, particularly for complex wounds that have traditionally been difficult to manage. For the medical technology industry, this collaboration represents another example of how specialized companies are combining forces to address complex clinical challenges through integrated solutions. More information about New Horizon Medical Solutions is available at https://www.nhmedical.com.
